The rate with the drug, which Merck sells under the brand name Keytruda, was 84.5% versus 76.8% for placebo recipients (P<0.001).
"The results of this trial support the use of pembrolizumab plus platinum-, taxane-, and anthracycline-containing neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery, as a treatment regimen for patients with high-risk, early triple-negative breast cancer, regardless of tumor PD-L1 expression status," Dr. Peter Schmid of Bart's Cancer Institute in London and colleagues conclude in the New England Journal of Medicine.
In 2020, the researchers reported that the drug produced a significantly better pathological complete response.
All 1,174 trial participants had untreated stage-II or -III disease.
The authors say the adverse events were consistent with known problems associated with both chemotherapy and pembrolizumab.
Merck paid for the study. The results were originally released July 15.
SOURCE: https://bit.ly/3oskFiq The New England Journal of Medicine, online February 9, 2022.
By Reuters Staff
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Endovascular therapy found effective for larger cerebral infarctions Next Article
Lower 5-year death rate with oral versus IV antibiotic therapy for endocarditis »
« Endovascular therapy found effective for larger cerebral infarctions Next Article
Lower 5-year death rate with oral versus IV antibiotic therapy for endocarditis »
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy